Takeshi Johkoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takeshi Johkoh has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Reoto Takei
Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan
3 shared publications - Tomoki Kimura
Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan
3 shared publications - Toshiaki Matsuda
Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan
3 shared publications - Yasuhiko Yamano
Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan
3 shared publications - Yoshikazu Inoue
Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan
3 shared publications - Ana Giménez
Radiology Department, Hospital de la Santa Creu i Sant Pau
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in Japanese Journal of Radiology
- p. 1-11
Assessment of fibrosing interstitial lung disease progression: CT visual score on radiological progressive pulmonary fibrosis criteria versus 3D-CT volume-histogram analysis
Purpose: To identify the most reproducible visual scoring approach on radiological criteria of the 2022 progressive pulmonary fibrosis (PPF) guideline and compare its association with pulmonary function test (PFT) decline against quantitative 3D-CT volume-histogram analysis (VHA) metrics in fibrosing interstitial lung disease (ILD). Materials and methods: In this single-center retrospective study, 92 patients with fibrosing ILD underwent paired thin-section CT and PFTs at a median 44.5-month interval. Five guideline-defined CT features were visually scored as a percentage of lung involvement on five axial sections at baseline and follow-up; the sum of changes in each feature constituted the total visual score change (ΔCT-score). Interobserver reliability was assessed using intraclass correlation coefficients (ICC). Quantitative metrics included changes in skewness, kurtosis, and entropy derived from VHA, and total-lung volume change (ΔV-LUNG) through volumetric analysis. Associations with changes in percent-predicted forced vital capacity (%FVC) and diffusing capacity for carbon monoxide (%DLCO) were evaluated using Spearman correlation coefficients. Discriminatory performance for disease progression was assessed using receiver operating characteristics. Results: ΔCT-score demonstrated excellent interobserver reliability (ICC, 0.94–0.96) and strong correlations with VHA metrics (Spearman r: Δskewness, − 0.78; Δkurtosis, − 0.74; Δentropy, 0.73). VHA metrics correlated substantially with Δ%FVC (r: Δskewness, 0.64; Δkurtosis, 0.61; Δentropy, − 0.61), comparable to ΔCT-score (r, − 0.60), whereas correlations with Δ%DLCO were moderate (r: Δskewness, 0.58; Δkurtosis, 0.55; Δentropy, − 0.58; ΔCT-score, − 0.48). ΔV-LUNG correlated with Δ%FVC (r, 0.61) and Δ%DLCO (r, 0.51). All correlations were statistically significant ( p < 0.001). All metrics showed good discriminatory performance for radiological and/or physiological evidence of disease progression by PPF guideline definition, with area-under-the-curve values of 0.76–0.89. Conclusion: VHA metrics demonstrated utility comparable to reproducible visual scoring for identifying radiological progression and physiological decline in fibrosing ILD. Automated VHA can offer an objective, reproducible alternative to laborious visual assessment for disease progression in fibrosing ILD.
- 17 September 2026
- Published by Springer Nature in Japanese Journal of Radiology
- p. 1-11
Open AccessAssessment of fibrosing interstitial lung disease progression: CT visual score on radiological progressive pulmonary fibrosis criteria versus 3D-CT volume-histogram analysis
Purpose: To identify the most reproducible visual scoring approach on radiological criteria of the 2022 progressive pulmonary fibrosis (PPF) guideline and compare its association with pulmonary function test (PFT) decline against quantitative 3D-CT volume-histogram analysis (VHA) metrics in fibrosing interstitial lung disease (ILD). Materials and methods: In this single-center retrospective study, 92 patients with fibrosing ILD underwent paired thin-section CT and PFTs at a median 44.5-month interval. Five guideline-defined CT features were visually scored as a percentage of lung involvement on five axial sections at baseline and follow-up; the sum of changes in each feature constituted the total visual score change (ΔCT-score). Interobserver reliability was assessed using intraclass correlation coefficients (ICC). Quantitative metrics included changes in skewness, kurtosis, and entropy derived from VHA, and total-lung volume change (ΔV-LUNG) through volumetric analysis. Associations with changes in percent-predicted forced vital capacity (%FVC) and diffusing capacity for carbon monoxide (%DLCO) were evaluated using Spearman correlation coefficients. Discriminatory performance for disease progression was assessed using receiver operating characteristics. Results: ΔCT-score demonstrated excellent interobserver reliability (ICC, 0.94–0.96) and strong correlations with VHA metrics (Spearman r: Δskewness, − 0.78; Δkurtosis, − 0.74; Δentropy, 0.73). VHA metrics correlated substantially with Δ%FVC (r: Δskewness, 0.64; Δkurtosis, 0.61; Δentropy, − 0.61), comparable to ΔCT-score (r, − 0.60), whereas correlations with Δ%DLCO were moderate (r: Δskewness, 0.58; Δkurtosis, 0.55; Δentropy, − 0.58; ΔCT-score, − 0.48). ΔV-LUNG correlated with Δ%FVC (r, 0.61) and Δ%DLCO (r, 0.51). All correlations were statistically significant ( p < 0.001). All metrics showed good discriminatory performance for radiological and/or physiological evidence of disease progression by PPF guideline definition, with area-under-the-curve values of 0.76–0.89. Conclusion: VHA metrics demonstrated utility comparable to reproducible visual scoring for identifying radiological progression and physiological decline in fibrosing ILD. Automated VHA can offer an objective, reproducible alternative to laborious visual assessment for disease progression in fibrosing ILD.
- Open Access
- 1 October 2022
- Published by Japan Society of Sarcoidosis and Other Granulomatous Disorders in The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
- Vol. 42 (1_2) , 43-46
CT findings of pulmonary sarcoidosis
CTは肺門,縦隔の対称性LN腫脹の描出に優れ,特に造影CTでは明瞭である.肺野の高分解能CT所見は典型的には気管支肺動脈周囲間質の不整な肥厚を中心とする広義間質肥厚,上肺野優位に分布する粒状,結節影が認められる.最末梢では,気管支肺動脈周囲間質の不整な肥厚は小葉中心性分岐粒状影となる.粒状,結節影はリンパ路である広義間質に沿って広がる.時にコンソリデーションや塊状影を示すことがある(pseudo alveolar pattern).微細分岐粒状影が集簇して,“銀河”ように見えるCT galaxy signも時にみられる.線維化に至る例は少ないが,進行すると上葉が収縮し気管支血管周囲に網状影,囊胞がみられる.まれに肺底部に“蜂巣肺”様の所見を示すことがある.
- 1 October 2022
- Published by Japan Society of Sarcoidosis and Other Granulomatous Disorders in The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
- Vol. 42 (1_2) , 43-46
Open AccessCT findings of pulmonary sarcoidosis
CTは肺門,縦隔の対称性LN腫脹の描出に優れ,特に造影CTでは明瞭である.肺野の高分解能CT所見は典型的には気管支肺動脈周囲間質の不整な肥厚を中心とする広義間質肥厚,上肺野優位に分布する粒状,結節影が認められる.最末梢では,気管支肺動脈周囲間質の不整な肥厚は小葉中心性分岐粒状影となる.粒状,結節影はリンパ路である広義間質に沿って広がる.時にコンソリデーションや塊状影を示すことがある(pseudo alveolar pattern).微細分岐粒状影が集簇して,“銀河”ように見えるCT galaxy signも時にみられる.線維化に至る例は少ないが,進行すると上葉が収縮し気管支血管周囲に網状影,囊胞がみられる.まれに肺底部に“蜂巣肺”様の所見を示すことがある.
- Top Cited PapersOpen Access
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (9) , e18-e47
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (9) , e18-e47
Top Cited PapersOpen AccessIdiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , 644-660
Human Oncoviruses and Thoracic Tumors: Understanding the Imaging Findings
Various oncoviruses are implicated in approximately 12%–25% of all human cancers as uncommon consequences of the normal viral life cycle, and the clinical setting and imaging findings can provide c... Approximately 1.4 million virus-induced cancers occur annually, representing roughly 10% of the cancer burden worldwide. Seven oncogenic DNA and RNA viruses (ie, oncoviruses) are implicated in appr... Created with BioRender.com
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , 644-660
Human Oncoviruses and Thoracic Tumors: Understanding the Imaging Findings
Various oncoviruses are implicated in approximately 12%–25% of all human cancers as uncommon consequences of the normal viral life cycle, and the clinical setting and imaging findings can provide c... Approximately 1.4 million virus-induced cancers occur annually, representing roughly 10% of the cancer burden worldwide. Seven oncogenic DNA and RNA viruses (ie, oncoviruses) are implicated in appr... Created with BioRender.com
- Open Access
- 19 October 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (11) , e0865
Anti‐MDA5 antibody‐positive clinically amyopathic dermatomyositis with diffuse alveolar damage diagnosed by transbronchial lung cryobiopsy: A case report
Diffuse alveolar damage (DAD) is known to be a pathological hallmark of acute respiratory distress syndrome or acute interstitial pneumonia, and to have a poor prognosis. We report a case of anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody‐positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP‐ILD), in which DAD was confirmed by transbronchial lung cryobiopsy at an early stage without respiratory failure. Although this patient initially did not show respiratory failure, his respiratory condition gradually worsened despite intensive immunosuppression therapy and he died 3 months later. Therefore, the early pathological findings of DAD did not match the clinical picture, which showed no respiratory failure. However, these findings were consistent with the subsequent course and poor outcome. Histological DAD, even in the absence of respiratory failure, may indicate a subsequent poor prognosis and explain the refractory course of RP‐ILD with anti‐MDA5 antibody‐positive CADM.
- 19 October 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (11) , e0865
Open AccessAnti‐MDA5 antibody‐positive clinically amyopathic dermatomyositis with diffuse alveolar damage diagnosed by transbronchial lung cryobiopsy: A case report
Diffuse alveolar damage (DAD) is known to be a pathological hallmark of acute respiratory distress syndrome or acute interstitial pneumonia, and to have a poor prognosis. We report a case of anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody‐positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP‐ILD), in which DAD was confirmed by transbronchial lung cryobiopsy at an early stage without respiratory failure. Although this patient initially did not show respiratory failure, his respiratory condition gradually worsened despite intensive immunosuppression therapy and he died 3 months later. Therefore, the early pathological findings of DAD did not match the clinical picture, which showed no respiratory failure. However, these findings were consistent with the subsequent course and poor outcome. Histological DAD, even in the absence of respiratory failure, may indicate a subsequent poor prognosis and explain the refractory course of RP‐ILD with anti‐MDA5 antibody‐positive CADM.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3276
Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis
Background: Attention has been focused on identifying cases with a progressive phenotype in interstitial lung abnormalities (ILA). Some ILA cases may be followed up as they are, some may be diagnosed with interstitial lung disease (ILD) as a result of work-up, including a surgical lung biopsy. Aims: To evaluate if the cases of idiopathic pulmonary fibrosis (IPF) with definition of ILA (ILA-IPF) differed from those of IPF without ILA (non-ILA-IPF). Methods: Of the patients diagnosed with IPF from January 2008 to July 2015, 149 ILA-IPF cases and 120 non-ILA-IPF cases were examined for various variables including disease progression and prognosis. ILA is defined based on the incidental identification of CT abnormality that are potentially compatible with ILD without previous clinical suspicion of ILD (Lancet Respir Med 2020; 8: 726–37). Results: In patients’ background at diagnosis of the two groups, significant differences were observed in age, PaO2, pulmonary function test, and exercise tolerance. Median overall survival was significantly longer in the ILA-IPF group (78.9 months vs 52.2 months, pLCO were significant prognostic factors. The prognosis adjusted by gender, age, FVC, and DLCO was not significantly different between ILA-IPF and non-ILA-IPF. (hazard ratio 0.79, 95% CI 0.56-1.11, p=0.18). Conclusion: No significant difference was observed in disease progression and prognosis between ILA-IPF and non-ILA-IPF. Early diagnosis of IPF in ILA patients is crucial.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3276
Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis
Background: Attention has been focused on identifying cases with a progressive phenotype in interstitial lung abnormalities (ILA). Some ILA cases may be followed up as they are, some may be diagnosed with interstitial lung disease (ILD) as a result of work-up, including a surgical lung biopsy. Aims: To evaluate if the cases of idiopathic pulmonary fibrosis (IPF) with definition of ILA (ILA-IPF) differed from those of IPF without ILA (non-ILA-IPF). Methods: Of the patients diagnosed with IPF from January 2008 to July 2015, 149 ILA-IPF cases and 120 non-ILA-IPF cases were examined for various variables including disease progression and prognosis. ILA is defined based on the incidental identification of CT abnormality that are potentially compatible with ILD without previous clinical suspicion of ILD (Lancet Respir Med 2020; 8: 726–37). Results: In patients’ background at diagnosis of the two groups, significant differences were observed in age, PaO2, pulmonary function test, and exercise tolerance. Median overall survival was significantly longer in the ILA-IPF group (78.9 months vs 52.2 months, pLCO were significant prognostic factors. The prognosis adjusted by gender, age, FVC, and DLCO was not significantly different between ILA-IPF and non-ILA-IPF. (hazard ratio 0.79, 95% CI 0.56-1.11, p=0.18). Conclusion: No significant difference was observed in disease progression and prognosis between ILA-IPF and non-ILA-IPF. Early diagnosis of IPF in ILA patients is crucial.
- Open Access
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1834
Prognosis in Non-IPF with Progressive Fibrotic Phenotype Results in Similar Prognosis in IPF
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1834
Open AccessPrognosis in Non-IPF with Progressive Fibrotic Phenotype Results in Similar Prognosis in IPF
- Open Access
- 1 January 2021
- Published by XMLink in Korean Journal of Radiology
- Vol. 22 (8) , 1416-1435
Non-Infectious Granulomatous Lung Disease: Imaging Findings with Pathologic Correlation
Franquet T, et al. Korean J Radiol. 2021 May;22:e69. https://doi.org/10.3348/kjr.2020.1082
- 1 January 2021
- Published by XMLink in Korean Journal of Radiology
- Vol. 22 (8) , 1416-1435
Open AccessNon-Infectious Granulomatous Lung Disease: Imaging Findings with Pathologic Correlation
Franquet T, et al. Korean J Radiol. 2021 May;22:e69. https://doi.org/10.3348/kjr.2020.1082
- Open Access
- 1 January 2021
- Published by Elsevier in European Journal of Radiology Open
- Vol. 8, 100334
Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study
- 1 January 2021
- Published by Elsevier in European Journal of Radiology Open
- Vol. 8, 100334
Open AccessProgression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study
- Top Cited PapersOpen Access
- 1 August 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (3) , e36-e69
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax. Methods: Systematic reviews were performed for six questions. The evidence was discussed, and then recommendations were formulated by a multidisciplinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Results: The guideline committee defined HP, and clinical, radiographic, and pathological features were described. HP was classified into nonfibrotic and fibrotic phenotypes. There was limited evidence that was directly applicable to all questions. The need for a thorough history and a validated questionnaire to identify potential exposures was agreed on. Serum IgG testing against potential antigens associated with HP was suggested to identify potential exposures. For patients with nonfibrotic HP, a recommendation was made in favor of obtaining bronchoalveolar lavage (BAL) fluid for lymphocyte cellular analysis, and suggestions for transbronchial lung biopsy and surgical lung biopsy were also made. For patients with fibrotic HP, suggestions were made in favor of obtaining BAL for lymphocyte cellular analysis, transbronchial lung cryobiopsy, and surgical lung biopsy. Diagnostic criteria were established, and a diagnostic algorithm was created by expert consensus. Knowledge gaps were identified as future research directions. Conclusions: The guideline committee developed a systematic approach to the diagnosis of HP. The approach should be reevaluated as new evidence accumulates.
- 1 August 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (3) , e36-e69
Top Cited PapersOpen AccessDiagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax. Methods: Systematic reviews were performed for six questions. The evidence was discussed, and then recommendations were formulated by a multidisciplinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Results: The guideline committee defined HP, and clinical, radiographic, and pathological features were described. HP was classified into nonfibrotic and fibrotic phenotypes. There was limited evidence that was directly applicable to all questions. The need for a thorough history and a validated questionnaire to identify potential exposures was agreed on. Serum IgG testing against potential antigens associated with HP was suggested to identify potential exposures. For patients with nonfibrotic HP, a recommendation was made in favor of obtaining bronchoalveolar lavage (BAL) fluid for lymphocyte cellular analysis, and suggestions for transbronchial lung biopsy and surgical lung biopsy were also made. For patients with fibrotic HP, suggestions were made in favor of obtaining BAL for lymphocyte cellular analysis, transbronchial lung cryobiopsy, and surgical lung biopsy. Diagnostic criteria were established, and a diagnostic algorithm was created by expert consensus. Knowledge gaps were identified as future research directions. Conclusions: The guideline committee developed a systematic approach to the diagnosis of HP. The approach should be reevaluated as new evidence accumulates.